Selective estrogen receptor modulator - Merck & CoAlternative Names: SERM - Merck
Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Developer Merck & Co
- Mechanism of Action Selective estrogen receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 10 Jul 2007 Discontinued - Phase-I with second unnamed SERM compound for Undefined women's health indication in USA (PO)
- 12 Sep 2006 Phase-I clinical trials with second unnamed SERM compound for Undefined women's health indication in USA (PO)